| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Thalidomide | FAERS: 3 | US FAERS | |
| 2 | Clofarabine | FAERS: 2 | US FAERS | |
| 3 | Dabigatran | FAERS: 1 | US FAERS | |
| 4 | Deferasirox | FAERS: 1 | US FAERS | |
| 5 | Doxorubicin | FAERS: 1 | US FAERS | |
| 6 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 7 | Minocycline | FAERS: 1 | US FAERS | |
| 8 | NuvaRing | FAERS: 1 | US FAERS | |
| 9 | Sofosbuvir | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | Tacrolimus | FAERS: 1 | US FAERS | |
| 11 | Vancomycin | FAERS: 1 | US FAERS | |
| 12 | Raloxifene Hydrochloride | OFFSIDES | ||
| 13 | alfacalcidol | OFFSIDES | ||
| 14 | brotizolam | OFFSIDES | ||
| 15 | mizoribine | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.